The Associations of Two Novel Inflammation Biomarkers, SIRI and SII, with Mortality Risk in Patients with Chronic Heart Failure
Di Zhu,Chi Wang,You Zhou,Hebin Che,Ruiqing Wang,Liting Cheng,Chongyou Rao,Qin Zhong,Zongren Li,Yongjie Duan,Kunlun He
DOI: https://doi.org/10.2147/jir.s451190
IF: 4.5
2024-02-23
Journal of Inflammation Research
Abstract:Di Zhu, 1, 2, &ast Chi Wang, 1, &ast You Zhou, 3 Hebin Che, 1 Ruiqing Wang, 1, 2 Liting Cheng, 3 Chongyou Rao, 1, 2 Qin Zhong, 1 Zongren Li, 1 Yongjie Duan, 1, 2 Kunlun He 1 1 Medical Big Data Research Center, Medical Innovation Research Department of PLA General Hospital, Beijing, 100853, People's Republic of China; 2 Graduate School of PLA General Hospital, Beijing, 100853, People's Republic of China; 3 School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China &astThese authors contributed equally to this work Correspondence: Kunlun He, Medical Big Data Research Center, Medical Innovation Research Department of PLA General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China, Tel +86-10-66939107, Email Background: The associations of two novel inflammation biomarkers, systemic inflammation response index (SIRI) and systemic immune inflammation index (SII), with mortality risk in patients with chronic heart failure (CHF) are not well-characterized. Methods: This retrospective cohort study included patients with CHF in two medical centers of Chinese People's Liberation Army General Hospital, Beijing, China. The outcomes of this study included in-hospital mortality and long-term mortality. Associations of SIRI and SII with mortality were assessed using multivariable regressions and receiver operating characteristic (ROC) analyses. Results: A total of 6232 patients with CHF were included in the present study. We documented 97 cases of in-hospital mortality and 1738 cases of long-term mortality during an average 5.01-year follow-up. Compared with patients in the lowest quartile of SIRI, those in the highest quartile exhibited 134% higher risk of in-hospital mortality (adjusted odds ratio, 2.34; 95% confidence interval [CI], 1.16– 4.72) and 45% higher risk of long-term mortality (adjusted hazard ratio, 1.45; 95% CI, 1.25– 1.67). Compared with patients in the lowest quartile of SII, those in the highest quartile exhibited 27% higher risk of long-term mortality (adjusted hazard ratio, 1.27; 95% CI, 1.11– 1.46). In ROC analyses, SIRI showed better prognostic discrimination than C-reactive protein (area under the curve: 69.39 vs 60.91, P = 0.01, for in-hospital mortality; 61.82 vs 58.67, P = 0.03, for 3-year mortality), whereas SII showed similar prognostic value with C-reactive protein. Conclusion: SIRI and SII were significantly associated with mortality risk in patients with CHF. SIRI may provide better prognostic discrimination than C-reactive protein. Keywords: systemic inflammation, systemic immune inflammation index, systemic inflammation response index, chronic heart failure, mortality risk Heart failure (HF) is a complex clinical syndrome caused by abnormal changes in heart structure and/or ventricular dysfunction, 1 with high readmission rates, disability rates, and mortality rates. Approximately 1–2% of the population had HF worldwide. 2 According to data from the China Hypertension Survey in 2012–2015, the prevalence of HF among Chinese population aged 35 years or greater was 1.3%. 3 With the increase in societal aging and the increasing prevalence of cardiovascular risk factors, HF will lead to a heavy burden on public health and socio-economic development. 4 Therefore, early identification of risk factors for adverse outcomes in patients with HF are crucial for early intervention and improving prognosis. A number of evidences showed that chronic systemic inflammation plays an essential role in the development of atherosclerosis and cardiovascular diseases (CVD). 5,6 However, compared with traditional inflammation biomarkers such as C-reactive protein (CRP) and interleukin-6, some novel inflammation biomarkers composed of several easily obtainable and reliable indicators may have greater clinical significance. Recently, systemic inflammation response index (SIRI) and systemic immune inflammation index (SII), two novel inflammation biomarkers that were calculated using blood counts, have been demonstrated to have greater power in predicting cardiovascular outcomes compared with CRP. 7–9 Analyses from Kailuan cohort study found that higher SIRI and SII were associated with increased risks of CVD and all-cause mortality in general population. 10,11 SII was also observed to predict adverse outcomes in patients with acute myocardial infarction, hypertension, and CVD. 12–14 Although, the associations of SIRI and SII with poor cardiovascular outcomes have been reported -Abstract Truncated-
immunology